68Ga-Trivehexin: Current Status of αvβ6-Integrin Imaging and Perspectives
Authors:
- Luca UrsoLuca Urso
- Rebecca NapolitanoRNRebecca Napolitano
- Giorgia SpeltriGSGiorgia Speltri
- Murat TuncelMTMurat Tuncel
- Ilham BadraneIBIlham Badrane
- Licia UccelliLicia Uccelli
- Francesca PortoFPFrancesca Porto
- Petra MartiniPetra Martini
- Alessandro NiorettiniANAlessandro Niorettini
- Corrado CittantiCCCorrado Cittanti
- Mirco BartolomeiMBMirco Bartolomei
- Alessandra BoschiAlessandra Boschi
Open Access
Abstract
Background/Objectives: Molecular imaging, especially PET, has advanced significantly, shifting from metabolic radiotracers like 2-deoxy-2-[18F]fluoro-D-glucose [18F]FDG to target-specific probes. Among these, αvβ6-integrin has emerged as a promising target in cancer and non-cancer diseases. This review focuses on the radiochemical properties and initial clinical applications of the [68Ga]Ga-Trivehexin PET probe. Methods: The literature review on [68Ga]Ga-Trivehexin systematically evaluated both preclinical and clinical studies, with particular emphasis on its radiochemical characteristics and preliminary clinical applications, while highlighting advancements, associated challenges, and the potential for future developments in the field. Results: This study highlights the significant advancements achieved with [68Ga]Ga-Trivehexin in the field of molecular imaging. The optimized multimeric system has substantially enhanced the radiotracer’s pharmacokinetic properties, binding affinity, and selectivity for αvβ6 integrin, demonstrating up to an 18-fold improvement compared to previous monomeric tracers. The synthesis protocol has been refined to achieve high radiochemical purity (>95%), essential for safe clinical use. Preliminary clinical applications, particularly in head and neck cancer (HNC) and pancreatic ductal adenocarcinoma (PDAC), have shown promising results, with high detection rates and improved differential diagnosis compared to [18F]FDG. Furthermore, [68Ga]Ga-Trivehexin PET/CT has shown potential in non-oncological conditions, such as idiopathic pulmonary fibrosis (IPF) and primary hyperthyroidism, suggesting broader clinical applicability. Conclusions: [68Ga]Ga-Trivehexin is a promising PET probe for imaging αvβ6-integrin in cancers and non-oncological diseases like idiopathic pulmonary fibrosis (IPF) and primary hyperparathyroidism (PHP).Keywords
This publication has 64 references indexed in Scilit:
- 68Ga-Trivehexin PET/CT uptake in malignant and fibrotic lung tissue: refining diagnostic applicationsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2025
- [68Ga]Ga-Trivehexin PET/CT imaging of integrin-αvβ6 expression in concomitant mucinous lung adenocarcinoma and idiopathic pulmonary fibrosisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2025
- The true negative [⁶⁸Ga]Ga-Trivehexin PET/CT in Solid Pseudopapillary Neoplasm of pancreas, mimicking pancreatic adenocarcinoma in [¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI scansEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- αvβ6-integrin targeted [68Ga]Ga-Trivehexin PET/CT imaging of a rare bronchial mucoepidermoid carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- 68Ga-Trivehexin PET/CT: a promising novel tracer for primary hyperparathyroidismEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Concomitant metastatic head-and-neck cancer and pancreatic cancer assessed by αvβ6-integrin PET/CT using 68Ga-Trivehexin: incidental detection of a brain metastasisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the “Cancer Integrin” αvβ6 with Ga-68-TrivehexinEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- PET/CT imaging of pancreatic carcinoma targeting the “cancer integrin” αvβ6European Journal of Nuclear Medicine and Molecular Imaging, 2021
- Stable Peptides Instead of Stapled Peptides: Highly Potent αvβ6‐Selective Integrin LigandsAngewandte Chemie International Edition, 2015